Latest Breaking News On - Aim lymphoma - Page 1 : comparemela.com

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., April 5, 2024 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April.

Curis incDrug administrationPrnewswire curis incCompany fourthRoche groupCompensation committeeFourth amendedIncentive planAim lymphomaAim leukemiaOrphan drug designation

Curis, Inc : Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc : Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Dennis riedlRoche groupCuris incPrnewswire curis incDrug administrationCompany fourthCompensation committeeFourth amendedIncentive planAim lymphomaAim leukemiaOrphan drug designation

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass., April 4, 2024 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James.

James dentzerCompany presentationCuris incPrnewswire curis incDrug administrationRoche groupChief executive officerAnnual needham virtual healthcare conferenceAim lymphomaAim leukemiaOrphan drug designation

Dr Nowakowski on the Use of Emavusertib in Relapsed/Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, discusses findings from the ongoing phase 1/2 TakeAim Lymphoma trial of emavusertib in combination with ibrutinib in patients with relapsed/refractory hematologic malignancies.

Grzegorzs nowakowskiDivision of hematologyMayo clinic comprehensive cancer centerClinical researchAim lymphomaTargeted approaches under assessment in amlOnclive tv

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James dentzerExchange commissionCuris incRoche groupDrug administrationTakeaim leukemia studyTakeaim leukemiaChief executive officerComplete responseAim leukemia studyAim lymphomaAim leukemiaOrphan drug designationNote regarding forward looking statementsSecurities litigation reform actOberland capital